Time Schedule
Monday, April 09 19:30-20:30 Opening Ceremony | 20:30-21:00 Keynote Speaker | 21:00-21:30 Discussion | 22:00 Dinner | Tuesday, April 10 07:00-08:00 Breakfast / Registration | 1st Session: Acute Coronary Syndrome (ACS): 08:00-09:15 | 08:00-08:25 Acute Coronary Syndrome Management: Current Challenges and Emerging Solutions. | 08:25-08:50 Dug Eluting Stent: An Update on Clinical Data. | 08:50-09:05 Antiplatelet Strategies in Acute Coronary Syndrome: Expanding Choices. | 09:15-09:30 Discussion | 09:30-09:40 Break | 2nd Session: Evolution of Antithrombotic Therapy Use in Acute Coronary Syndrome: 09:40-10:45 | 9:40-10:05 Anticoagulant in ACS and Beyond. | 10:05-10:30 Newer Antiplatelet: Confronting the Limitations of Antiplatelet Therapy. | 10:30-10:55 Risk of Bleeding: Balancing Risk and Benefit. | 10:55-11:10 Discussion | 11:10-11:20 Break | 3rd Session: Heart Failure (HF): 11:20-12:15 | 11:20-11:45 Heart Failure: Current Medical Therapy. | 11:45-12:10 Heart Rate as a Therapeutic Target in Heart Failure Patients. | 12:10-12:35 Devices and Technology in the Management of Heart Failure. | 12:35-12:50 Discussion | 12:50-14:00 Prayer Time, Lunch Break, Exhibition | 4th Session: Hypertension: 14:00-16:00 | 14:00-14:25 Update on Hypertension Management. | 14:25-14:50 JNC 8 (VIII): What is new going to be in the guidelines? | 14:50-15:15 Strategies for the Management of Resistant Hypertension. | 15:15-15:30 Discussion, Prayer Time | 5th Session: Ambulatory care in Cardiology: 15:30-16:45 | 15:30-15:55 Medication safety concerns in the cardiovascular patient. | 15:55-16:20 Lipid management: Optimizing Therapies Old and New. | 16:20-16:45 Primary prevention of cardiovascular disease: Tools and Strategies. | 16:45-17:00 Discussion | Wednesday, April 11 07:00-08:00 Breakfast / Registration | 1st Session: Atrial fibrillation (Afib): 08:00-09:15 | 08:00-08:25 Contemporary approach in Atrial Fibrillation Management. | 08:25-08:50 Antithrombotic Therapy in Afib: Defining the future of Oral Anticoagulant Therapy. | 08:50-09:15 Combined Atrial Fibrillation and Heart Failure: Challenges in Pharmacotherapy Management. | 09:15-09:30 Discussion | 09:30-09:40 Break | 2nd Session: End stage Heart Failure and Heart Transplant: 09:30-10:45 | 09:40-10:05 ICU Management of End Stage Heart Failure and Mechanical Circulatory Support Therapy. | 10:05-10:30 Heart Transplant: indication, selection, pre and post op care. | 10:30-10:55 Long Term Management of Heart Transplant and the Pharmacist Role. | 10:55-11:10 Discussion | 11:10-11:20 Break | 3rd Session: Venous Thromboembolism (VTE) Challenge and Valvular Heart Disease (VHD) Management: 11:00-12:15 | 11:20-11:45 VTE: Acute and Chronic Management. | 11:45-12:10 Contemporary Management of VHD in Various Medical Settings. | 12:10-12:35 Transcatheter Aortic Valve Implantation (TAVI): Highlight on Procedural and Pharmacotherapy Management Implications. | 12:35-12:50 Discussion | 12:50-14:00 Prayer Time, Lunch Break, Exhibition | 4th Session: Personalized Medicine in Cardiology: 14:00-16:00 | 14:00-14:25 Antiplatelet resistant / un-responsiveness: Genomic Markers and Advanced Testing. | 14:25-14:50 Tailored antiplatelet therapy: Pharmacogenomics or Dynamic Applications? | 14:50-15:15 Women cardiology: Differences in Diagnosis and Management. | 15:15-15:30 Discussion, Prayer | 5th Session: Pulmonary Hypertension: 15:30-16:45 | 15:30-15:55 Diagnosis and Treatment of Pulmonary Hypertension. | 15:55-16:20 Pulmonary Hypertension in ICU Setting. | 16:20-16:45 Perspectives on Pharmacoeconomic Appropriateness of Pulmonary Hypertension Medications. | 16:45-17:00 Discussion | 17:00-17:30: Closing Ceremony
Slider

Platinum Sponsors:

Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.


To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.



Website: http://www.pfizer.com

Silver Sponsors:

Sanofi-aventis is managing the promotion of its brands in Saudi Arabia. Scientifically supported by a regional medical and marketing staff based in Jeddah, sanofi-aventis provides patients and healthcare professionals in Saudi Arabia with efficient and effective therapeutic responses to diseases in our 7 major therapeutic areas.

Sanofi-aventis in Saudi Arabia is not only committed to providing the most efficient and reliable medicines to patients, but also to improving their quality of life.



Website: http://sa.sanofi-aventis.com/l/sa/en/index.jsp

More Sponsors:

Riyadh Pharma




Website: http://www.servier.com/

Bayer HealthCare Pharmaceuticals' goal is to discover products that will improve human health worldwide by diagnosing, preventing and treating diseases. As a specialty pharmaceutical company, we focus our efforts where we can have the most impact.

For more than 100 years, Bayer has been dedicated to developing, manufacturing and marketing pharmaceuticals. Built on the company's long history of providing medicines that healthcare providers and patients can trust, Bayer is one of the most recognized brands in health care.



Website: http://pharma.bayer.com/scripts/pages/en/index.php

Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, focusing on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.



Website: http://www.actelion.com/en/index.page

Jazeera Pharmaceutical Industries ( JPI) is a Saudi pharmaceutical manufacturer. Established in the year 1999, JPI's main objective was to manufacture and market high quality healthcare products at a reasonable cost satisfying patient needs in Saudi Arabia and other neighboring markets. Another collateral objective was to be an active participant in reaching regional self-sufficiency in healthcare products and be an essential contributor in enhancing the nation's economic development.



Website: http://www.jpi.com.sa

Al Kamal

Sponsors